🇺🇸 FDA
Patent

US 10258573

Micronized insulin and micronized insulin analogues prepared under acidic conditions, and methods of manufacturing the same under acidic conditions

granted A61KA61K38/28A61K9/0075

Quick answer

US patent 10258573 (Micronized insulin and micronized insulin analogues prepared under acidic conditions, and methods of manufacturing the same under acidic conditions) held by Amphastar Pharmaceuticals, Inc. expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Amphastar Pharmaceuticals, Inc.
Grant date
Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K38/28, A61K9/0075, A61K9/008, A61K9/14